11 – 20 of 51
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2022
-
Mark
Immune tolerance induction in the era of emicizumab – still the first choice for patients with haemophilia A and inhibitors?
- Contribution to journal › Article
-
Mark
Pain, depression and anxiety in people with haemophilia from three Nordic countries : Cross-sectional survey data from the MIND study
- Contribution to journal › Article
- 2021
-
Mark
Validation of factor VIII activity for monitoring standard and extended half-life products and correlation to thrombin generation assays
- Contribution to journal › Article
-
Mark
Real-world prophylactic usage of recombinant factor VIII Fc in Sweden : A report from the Swedish national registry for bleeding disorders
- Contribution to journal › Letter
-
Mark
Optimising prophylaxis in haemophilia A : The ups and downs of treatment
- Contribution to journal › Scientific review
- 2020
-
Mark
Clinical utility and impact of the use of the chromogenic vs one-stage factor activity assays in haemophilia A and B
- Contribution to journal › Scientific review
- 2019
-
Mark
Recombinant factor VIII products and inhibitor development in previously untreated patients with severe haemophilia A : Combined analysis of three studies
- Contribution to journal › Article
- 2018
-
Mark
Pharmacokinetic modelling and validation of the half-life extension needed to reduce the burden of infusions compared with standard factor VIII
- Contribution to journal › Article
-
Mark
Defining extended half-life rFVIII-A critical review of the evidence
- Contribution to journal › Article
-
Mark
Immune tolerance induction : What have we learned over time?
- Contribution to journal › Scientific review
